Key facts
| Price (PPV) | 15,611 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | lenvatinib |
| Class | Antineoplastic agents |
| ATC code | L01XE29 |
| Manufacturer | SOTHEMA |
| Presentation | Boite de 30 |
| Hospital price | 15,313 MAD |
| Data collected on | 9/8/2026 |
Indications
LENVIMA est indiqué en monothérapie dans le traitement des patients adultes atteints de carcinome thyroïdien différencié (papillaire, folliculaire, à cellules de Hürthle) localement avancé ou métastatique, réfractaire à l’iode radioactif (IRA) et progressif. LENVIMA est indiqué en monothérapie pour le traitement des patients adultes atteints de carcinome hépatocellulaire (CHC) avancé ou non résécable qui n’ont pas reçu de traitement systémique antérieur.
Find an open pharmacy
On-call pharmacies near you
About Lenvima 4 mg
Lenvima 4 mg belongs to the antineoplastic agents therapeutic class. In Morocco, this drug is marketed by SOTHEMA and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Lenvima 4 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Lenvima 4 mg
Answers to common questions from Moroccan patients about this drug.